ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

21 - 23 September 2016, Vienna, Austria

Conference Objectives

Background: Antimicrobial drug resistance is an urgent problem. There are relatively few agents in developmental pipelines. Traditional pathways for drug development are expensive and slow. Both the EMA and FDA have recognized some of these obstacles for drug development. New regulation now enables accelerated drug development, with adaptive licensing until larger definitive phase III studies are completed. Such an approach enables access to drugs for patients with unmet medical needs.

Challenges: There is uncertainty regarding what constitutes reasonable pathways for accelerated drug development. There is a reliance on very robust preclinical studies, innovative clinical trial design, strong academicindustrial partnerships, and a requirement for early engagement with regulatory bodies.

CME Accreditation

The conference was granted 13 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Organizing Committee

  • David Hooper, Boston, MA, United States
  • William Hope, Liverpool, United Kingdom
  • Gunnar Kahlmeter, Växjö, Sweden
  • Ursula Theuretzbacher, Vienna, Austria

Programme Committee

  • David Andes, Madison, WI, United States
  • Marco Cavaleri, London, United Kingdom
  • Ed Cox, Silver Spring, MD, United States
  • George Drusano, Lake Nona, FL, United States
  • William Hope, Liverpool, United Kingdom
  • Gunnar Kahlmeter, Växjö, Sweden
  • Jason Roberts, Brisbane, Australia
  • Keith Rodvold, Chicago, IL, United States
  • Ursula Theuretzbacher, Vienna, Austria

Scientific Secretariat
William Hope
Thomas Greif

ESCMID Executive Office
Gerbergasse 14
4001 Basel, Switzerland

Phone +41 61 508 01 54